Sign in
Taking peoplePhase 3

Compares a trial medicine, MK-8748, with aflibercept for diabetic macular edema

Tests MK-8748 against aflibercept in adults with diabetic macular edema.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Mladá Boleslav, Náchod, Pardubice V, Prague, and Prague 5, CzechiaSee the 7 sitesAlso in 10 other countries, 90 sites
Trial code
Registry title
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Status
Recruiting
Phase
Phase 3
People taking part
960 people, planned
Started
27 Aug 2026
Expected to end
31 Oct 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MK-8748
  • Aflibercept
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or type 2 diabetes whose vision has dropped mainly because of diabetic macular edema (swelling in the centre of the retina).

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Diabetic macular edema in the study eye, causing a decrease in vision. If never treated for it, the diagnosis must be within 9 months of screening. If treated before, the first treatment must be no longer than 3 years before screening.
Earlier treatment
People who never had treatment for diabetic macular edema must have been diagnosed within 9 months of screening. People who had treatment must have had their first treatment no longer than 3 years before screening.
Biomarker or test result
Hemoglobin A1c (HbA1c) of ≤12% (108 mmol/mol).

Main reasons for not taking part

  • Kidney failure needing a kidney transplant or dialysis, or expected to need dialysis during the study
  • Stroke or heart attack within 180 days before the first dose
  • Newly diagnosed or untreated diabetes with diabetes medicine started within 3 months before the first dose
  • Cataract or minimally invasive glaucoma surgery in the study eye within 90 days of screening
  • Advanced or uncontrolled glaucoma, past retinal detachment, other active retinal disease in the study eye, or uncontrolled blood pressure

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%
  • Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)
  • For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Who cannot take part

  • Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention
  • Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening
  • Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention
  • Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening
  • Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye
  • Has active retinal disease other than the condition under investigation in the study eye
  • The main exclusion criteria include but are not limited to the following:
  • Has advanced or uncontrolled glaucoma in the study eye
  • Has uncontrolled blood pressure at screening

Where in Czechia

Also in 10 other countries, 90 sites

  • Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho krajeMladá Boleslav, CzechiaNot yet recruiting
  • VISUS, spol s.r.o.Náchod, CzechiaNot yet recruiting
  • Oftex s.r.o.Pardubice V, CzechiaNot yet recruiting
  • Astra Clinic.s.r.o.Prague, CzechiaNot yet recruiting
  • Fakultni nemocnice Kralovske VinohradyPrague, CzechiaNot yet recruiting
  • Vseobecna fakultni nemocnice v PrazePrague, CzechiaNot yet recruiting
  • Axon Clinical s.r.o.Prague 5, CzechiaNot yet recruiting

About the trial

What the trial wants to find out

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person.

Read full original descriptionShow less

The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.

The 3 groups in the trial

  • MK-8748 Low DoseTreatment being tested

    Participants receive 5 initial administrations of MK-8748 low dose every 4 weeks (Q4W), then continue to receive MK-8748 low dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.

    Treatment: MK-8748

  • MK-8748 High DoseTreatment being tested

    Participants receive 5 initial administrations of MK-8748 high dose every 4 weeks (Q4W), then continue to receive MK-8748 high dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.

    Treatment: MK-8748

  • Aflibercept 2 mgExisting treatment, for comparison

    Participants receive 5 initial administrations of aflibercept 2 mg every 4 weeks (Q4W), then continue to receive aflibercept 2mg every 8 weeks (Q8W) until week 100.

    Treatment: Aflibercept

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Plain-language title
Compares a trial medicine, MK-8748, with aflibercept for diabetic macular edemaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 17 November 2026.
Record updated
12 November 2026